Attune
Manufacturing · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
250 W 55th St Fl 34, New York City, New ...Phone Number
(646) 597-6987Website
www.attunepharmaceutical.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Attune
Attune Pharmaceuticals is dedicated to pioneering novel treatments for rare diseases through the development of innovative, orally-administered small-molecule therapeutics. The company focuses on targeting serine proteases to enhance patient outcomes and improve quality of life. Their lead drug candidate, ATN-249, has shown promising results in preclinical studies, indicating a favorable safety profile and potential for once-a-day dosing. Attune Pharmaceuticals aims to empower clinicians and provide well-tolerated therapies for patients worldwide.Explore more
Popular SearchesAttune PharmaceuticalsAttune Pharmaceuticals IncSIC Code 28,283NAICS Code 32,325Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Attune your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Attune had a recent Job posting/layoffs
Check if Attune has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Attune
Attune, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Attune has new funding data
Product Launch: Get notified when Attune launches new products
Website visits: Recent activity has been detected on your website
Check out if Attune is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Attune recently announced quarterly report
Recommended Actions
Find VP level buyers at Attune
Find 2 more new buyers
Attune financials insights
Gather financial insights about Attune, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series B
$23M
Attune Tech Stack
A closer look at the technologies used by Attune
See more technologies
Attune News & Media
Attune Pharmaceuticals Closed $23M Series B Financing
Attune Pharmaceuticals, Inc., a NYC-based biotechnology company focused on the discovery and development of novel, orally-administered, small molecule therapeutics for the treatment of rare diseases, closed a $23m Series B financing. The round was led by Venrock Healthcare Partners joined by new investor LifeSci Venture Partners, and existing investors RTW Investments, RA Capital, Boxer Capital […] The post Attune Pharmaceuticals Closed $23M Series B Financing appeared first on FinSMEs.Attune Pharmaceuticals Secures $23M
NEW YORK, NY, Attune Pharmaceuticals today announced the completion of a $23 million Series B financing.Attune Pharmaceuticals Announces $23M Series B Financing to Advance ATN-249 for the Treatment of HAE
NEW YORK, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Attune Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of novel, orally-administered, small molecule therapeutics for the treatment of rare diseases, today announced the completion of a $23 million Series B financing.Attune Pharmaceuticals Announces Positive Phase 1 Results for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAE
NEW YORK, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Attune Pharmaceuticals, a biotechnology company focused on the discovery and development of novel oral small molecule therapeutics for treatment of rare diseases, today announced positive results from the first in human studies evaluating ATN-249, a novel orally administered plasma kallikrein inhibitor for the treatment of Hereditary Angioedema (HAE). The data were presented by Ira Kalfus, M.D., chief medical officer of Attune, as a poster presentation
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Attune
Sign Up For FreeTo access detailed company insights
Attune Pharmaceuticals is dedicated to pioneering novel treatments for rare diseases through the development of innovative, orally-administered small-molecule therapeutics. The company focuses on targeting serine proteases to enhance patient outcomes and improve quality of life. Their lead drug candidate, ATN-249, has shown promising results in pre... Read More
